Why the study?
Does the presence of preformed cardiac myosin autoantibodies increase the risk of acute rejection after heart transplantation in patients with dilated cardiomyopathy?
Does the presence of preformed cardiac myosin autoantibodies increase the risk of acute rejection after heart transplantation in patients with dilated cardiomyopathy?
Preformed IgG3 and IgM cardiac myosin autoantibodies in patients with dilated cardiomyopathy are associated with more frequent and severe acute cardiac rejection after heart transplantation.
No takes yet. Share an insight, caveat, or question.
May signal higher rejection risk in DCM transplant recipients; leaves open whether autoantibody screening alters management.
Warraich et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: